Releases Trend Coverage on TWTR, DRNA, PVCT, and GERN

Publishing & Media

Share Tweet Releases Trend Coverage on TWTR, DRNA, PVCT, and GERN

Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at to get exclusive access to our free stock reports.

Twitter, Inc. (NYSE: TWTR) shares moved up 6.76 percent on Thursday to close at $63.47 with nearly 17.5 million shares traded. The stock was one of the most active stocks on the NYSE. The stock’s gain came on the heels of Facebook posting an upbeat earnings report. Twitter won’t report until Wednesday next week.

Get more information on Twitter, Inc. and free access to the in-depth equity report at:                                   

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) made its impressive IPO debut in the market on Thursday. Dicerna opened at $30.00 even though its IPO was priced at $15.00. DRNA is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. DRNA is using its RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas.

Get more information on Dicerna Pharmaceuticals, Inc. and free access to the in-depth equity report at:

Provectus Biopharmaceuticals, Inc. (OTC: PVCT) shares closed down 26.31 percent on Thursday with about 7.2 million shares traded. The stock was one of the biggest decliners in the OTC marketplace. The company and XenoTech, a preclinical CRO and pioneer in collaborative research surrounding in vitro drug metabolism and pharmacokinetics (DMPK) services, announced recently that an article describing a study to determine the potential of rose bengal disodium to cause drug-drug interactions has been published by Xenobiotica, a peer-reviewed scientific journal that publishes comprehensive research papers on pharmacokinetics.

Get more information on Provectus Biopharmaceuticals, Inc. and free access to the in-depth equity report at:                                                            

Geron Corporation (NASDAQ: GERN) shares closed up 23.56 percent with nearly 34 million shares traded. The stock had one of the biggest volume advances on the NASDAQ on Thursday. The company announced the pricing of its previously announced underwritten public offering of 22,500,000 shares of its common stock, offered at a price to the public of $4.00 per share. The gross proceeds to Geron from this underwritten public offering are expected to be approximately $90 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron.

Get more information on Geron Corporation and free access to the in-depth equity report at:       


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.